RBRC05478

Information1

Image
BRC No.RBRC05478
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6;129S4-ECAT11<tm1Yam>
Former Common nameB6-ECAT11/GFP KI
H-2 Haplotype
ES Cell lineRF8 [129S4/SvJae]
Background strain
Appearance
Strain developmentDevelopr by Kumiko A. Iwabuchi and Shinya Yamanaka, Center for iPS Cell Research and Application, Kyoto University in 2011. C57BL/6J and 129S4 mixed background.
Strain descriptionECAT11 (L1td1) knockout mice. The coding region of ECAT11 gene was replaced with EGFP, IRES and a puromycin resistant cassette. Homzygous mutant mice show no obvious abnormality.
Colony maintenanceHomozygote x Homozygote [or Crossing to C57BL/6JJJcl]
ReferencesPLoS One, 6, e20461 (2011). 21637830

Health Report

Examination Date / Room / RackNo Data

Gene

Gene info
Gene symbolGene nameChr.Allele symbolAllele namePromoter
L1td1LINE-1 type transposase domain containing 14L1td1<tm1Yam>targeted mutation 1, Shinya Yamanaka

Gene symbolGene nameChr.Allele symbolAllele namePromoter
EGFPEnhanced Green Fluorescent Protein, F64L and S65T (Aequorea victoria)4EGFP

Gene symbolGene nameChr.Allele symbolAllele namePromoter
Frtyeast FRT (flippase recombination target) site4Frt

Gene symbolGene nameChr.Allele symbolAllele namePromoter
GHGrowth hormone polyA (Bovine)4GH

Gene symbolGene nameChr.Allele symbolAllele namePromoter
Iresinternal ribosomal entry site (EMCV)4

Gene symbolGene nameChr.Allele symbolAllele namePromoter
puropuromycin resistance gene (Streptomyces alboniger)4puro

Information2

Donor DNAA.victoria EGFP cDNA, Encephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), S. alboniger Puromycin resistance gene, Bovine growth hormone polyA sequence, S.cerevisiae FRT (flippase recombination target) site
Research applicationFLP/frt system
Fluorescent Proteins/lacZ System
Specific Term and Conditions(1) The RECIPIENT belongs to a not-for-profit academic organization (i.e. a university or another institution of higher education or any nonprofit scientific or educational organization, including government agencies).
(2) The RECIPIENT recognizes and acknowledges that KYOTO UNIVERSITY retains the ownership of:
(a) BIOLOGICAL RESOURCE (hereinafter referred as the “ORIGINAL MATERIAL”),
(b) unmodified descendant from the ORIGINAL MATERIAL (hereinafter referred as the “PROGENY”), and
(c) substances created by the RECIPIENT which constitute an unmodified functional subunit of or product expressed by the ORIGINAL MATERIAL (hereinafter referred as the “UNMODIFIED DERIVATIVES”).
The RECIPIENT retains ownership of:
(a) substances created by the RECIPIENT which contain/incorporate the ORIGINAL MATERIAL, PROGENY and UNMODIFIED DERIVATIVES (hereinafter referred as the “MODIFICATIONS”), except that, the KYOTO UNIVERSITY retains ownership rights to the ORIGINAL MATERIAL, PROGENY and UNMODIFIED DERIVTIVES therein, and
(b) those substances created through the use of the ORIGINAL MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVTIVES or MODIFICATIONS.
(3) The RECIPIENT recognizes and acknowledges that the ORIGINAL MATERIAL was created by the scientist at KYOTO UNIVERSITY by utilizing the Red/ET Recombineering technology of Gene Bridges GmBH.
(4) The RECIPIENT shall not use the ORIGINAL MATERIAL, PROGENY and UNMODIFIED DERIVATIVES for any purpose other than the academic research purpose of conducting the research set forth in the MATERIAL TRANSFER AGREEMENT (hereinafter referred as “RESEARCH PROJECT”).
(5) The RECIPIENT shall receive the prior written approval from KYOTO UNIVERSITY, if the RECIPIENT uses the ORIGINAL MATERIAL, PROGENY and UNMODIFIED DERIVATIVES with anyone else outside of the RECIPIENT’S laboratory to carry out the RESEARCH PROJECT.
(6) The ORIGINAL MATERIAL, PROGENY and UNMODIFIED DERIVATIVES shall be used only by the RECIPIENT and others working under RECIPIENT’S direct supervision at the RECIPIENT laboratory, and shall not be used by, as well as shall not be distributed and assigned to anyone else either at the RECIPIENT organization or outside the organization.
(7) At the time of publication of the result from using the BIOLOGICAL RESEOURCE in the RESEARCH PROJECT, whether in print or in electronic form, the RECIPIENT shall provide a copy of each publication to KYOTO UNIVERSITY.
iPS Cells Team
Center for iPS Cell Research and Application (CiRA), Kyoto University
E-mail: cira-keiyaku@cira.kyoto-u.ac.jp
FAX: 81-75-366-7023
URL: http://www.cira.kyoto-u.ac.jp/e/index.html
(8) The RECIPIENT acknowledges that this Agreement is not the agreement to license the intellectual property rights relating the ORIGINAL MATERIAL, PROGENY and UNMODIFIED DERIVATIVES owned by KYOTO UNIVERSITY to the RECIPIENT. The RECIPIENT also acknowledges that no express or implied licenses or other rights are provided to the RECIPIENT from KYOTO UNIVERSITY to use the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES, or any related patents of KYOTO UNIVERSITY for commercial purposes.
(9) The RECIPIENT agrees to grant to KYOTO UNIVERSITY royalty-free licenses, which are acquired by its use of the ORIGINAL MATERIAL, PROGENY and UNMODIFIED DERIVATIVES, for teaching and academic research purposes, and will not exercise their intellectual property rights to KYOTO UNIVERSITY.
(10) The RECIPIENT agrees that any handling or other activities undertaken in their laboratory with the ORIGINAL MATERIAL shall be conducted in compliance with all applicable laws, regulations, guidelines and rules. The RECIPIENT shall, if necessary, take any steps or procedures to comply with legal requirements of handling of the ORIGINAL MATERIAL.
(11) The RECIPIENT agrees that KYOTO UNIVERSITY makes no representations and extends no warranties of any kind, either expressed or implied. There are no express or implied warranties of merchantability or fitness for a particular purpose, or that the use of the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES, MODIFICATION and any substances derived from the ORIGINAL MATERIAL will not infringe any patent, copyright, trademark, or other proprietary rights. The RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES, MODIFICATION and any substances derived from the ORIGINAL MATERIAL. KYOTO UNIVERSITY will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or claim or demand by any other party made against the RECIPIENT, due to or arising from the use of the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES, MODIFICATION and any substances derived from the ORIGINAL MATERIAL by the RECIPIENT.
(12) The RECIPIENT shall cite the paper specified below in any publication of the result from the RESEARCH PROJECT.
Iwabuchi KA et al. ECAT11/L1td1 is enriched in ESCs and rapidly activated during iPSC generation, but it is dispensable for the maintenance and induction of pluripotency. PLoS One. 2011;6(5):e20461. Epub 2011 May 26.
(13) The RECIPIENT agrees that RIKEN informs to KYOTO UNIVERSITY of the RECIPIENT name, the RECIPIENT institution, the title of the RESEARCH PROJECT and the date of distribution.
DepositorShinya Yamanaka (Kyoto University)
Strain Statusan icon for Frozen embryosFrozen embryos
an icon for Frozen spermFrozen sperm
Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
Cryopreserved sperm (within 1 month)
Cryopreserved embryos (within 1 month)
Additional Info.Genotyping protocol -PCR-
GFP Transfer License (Japanese / English)
Please fill in the Schedule A, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read Schedule B.

BRC mice in Publications

No Data